Evaluation of Anti-mullerian Hormone(AMH) Levels as a Predictive Factor of Response to Weight Loss Treatment in Obese Infertile Women With Poly Cystic Ovary(PCOS)
Evaluation of Anti-mullerian Hormone(AMH) Levels as a Predictive Factor of Response to Weight Loss Treatment in Obese Infertile Women With Poly Cystic Ovary(PCOS)
This study is a prospective before & after clinical trial to compare the basal and 3 months
 after diet anti-mullerian hormone levels between responders and non-responders to weight loss
 diet in obese infertile women with PCOS population
The study population comprised of all obese infertile PCOS patients aged 20-40 years which
 underwent 3 months weight loss diet in royan institute, Tehran Iran.

 The study is conducted over 12 wk energy restriction. All subjects have the same dietary
 protocol. At baseline, week 12 the levels of AMH,Follicular Stimulating Hormone (FSH),
 Lutienizing Hormone(LH),Prolactin (PRL), androgens, sex hormone-binding globulin (SHBG),
 glucose, and insulin were measured and Free Androgen Index (FAI) and Insulin Resistance (IR)
 indices is calculated. The laboratory tests are determined by radioimmunoassay in the
 Laboratory of Endocrinology of Royan institute. AMH is measured in duplicate using an
 ultrasensitive ELISA kit (AMH-ELIZA Kit; Beckman Coulter, Marseilles, France) according to
 manufacturer instructions. All measurements are performed using a single kit and at the same
 time in the Laboratory of clinical Immunology of Royan institute.

 Data collection will be performed by using questionnaire to be filled as per the available
 records and laboratory results. Data analysis will be done through descriptive and perceptive
 statistical methods.
Inclusion Criteria:

 - 1- diagnosis of PCOS, according to the Rotterdam Consensus Workshop Group, by 2 of the
 following 3 criteria: menstrual irregularity (cycle length<26 d or >31 d or variation
 between consecutive cycles of >3 d); clinical (hirsutism assessed by a Ferriman-Gallwey
 score > 8) or biochemical [free androgen index (FAI) > 5.4 or testosterone_1.4 nmol/L]
 hyperandrogenism; or positive ultrasound presentation of polycystic ovaries by transvaginal
 scan.

 2- Age between 18 -40

 Exclusion Criteria:

 - 1. Body mass index (BMI; in kg/m2) < 30, 2. Type 2 diabetes mellitus and related
 endocrinopathic disorders [identified by assessment of thyroid-stimulating hormone (TSH),
 prolactin, and 17_hydroxyprogesterone].

 3. Regular exercise activities during the study. 4. Cases of alcoholism and smoking. 5. The
 use of endocrine hormonal treatment or insulin-sensitizing agents is not permitted during
 either phase of the study, and the use of oral contraceptives is not permitted during of
 the study. Subjects are required to cease taking oral contraceptives 4 wk and hormonal
 treatment or insulin-sensitizing agents 2 wk before commencement of the short-term study
 phase.